CATX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CATX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Perspective Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. Perspective Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2025-04-06), Perspective Therapeutics's share price is $1.80. Perspective Therapeutics's Median PS Value is $0.00. Therefore, Perspective Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Perspective Therapeutics's Median PS Value or its related term are showing as below:
During the past 13 years, the highest Price to Median PS Value of Perspective Therapeutics was 3.40. The lowest was 0.72. And the median was 1.09.
The historical data trend for Perspective Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Dec23 | Dec24 | |||||||||||
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
7.46 | 5.64 | 4.19 | - | - |
Perspective Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Medical Devices subindustry, Perspective Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's Price-to-Median-PS-Value falls into.
Perspective Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
Perspective Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (AMEX:CATX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Perspective Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 1.80 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Perspective Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Heidi Henson | director | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
Johan M. Spoor | director, officer: CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Jonathan Robert Hunt | officer: Chief Financial Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Williamson Robert F Iii | director | 140 LASALLE AVENUE, PIEDMONT CA 94610 |
Lori A Woods | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Markus Puhlmann | officer: Chief Medical Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Frank Morich | director | 40 GUEST STREET, BOSTON MA 02135 |
Mark John Austin | officer: Controller/Prin Fin&Acct Offic | 350 HILLS ST, STE 106, RICHLAND WA 99354 |
Alan Hoffmann | director | 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032 |
Michael W Mccormick | director | 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260 |
William Cavanagh | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Philip J Vitale | director | 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255 |
Michael Krachon | officer: VP of Sales & Marketing | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Krista Cline | officer: Dir. of Operations, Secretary | 350 HILLS STREET, STE 106, RICHLAND WA 99354 |
Jennifer Streeter | officer: VP of Human Resources | 350 HILLS STREET SUITE 106, RICHLAND WA 99354 |
From GuruFocus
By GuruFocus Research • 03-30-2024
By Marketwired Marketwired • 01-31-2020
By GuruFocus News • 11-12-2024
By PRNewswire PRNewswire • 10-28-2022
By GuruFocus Research • 09-23-2024
By PRNewswire PRNewswire • 10-28-2022
By GuruFocus Research • 09-18-2024
By PRNewswire PRNewswire • 01-06-2021
By GuruFocus News • 10-02-2024
By GuruFocus Research GuruFocus Editor • 04-12-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.